| AUTOLUS THERAP. SP.ADR/1 |
| USA |
| Gesundheit |
| US05280R1005 / A2JNZJ |
| 6A3A (Frankfurt) / AUTL (NASDAQ) |
| FRA:6A3A, ETR:6A3A, 6A3A:GR, NASDAQ:AUTL |
| - |
| https://www.autolus.com/ |
|
Autolus Therapeutics plc American Depositary Receipt represents shares in Autolus Therapeutics plc, a clinical-stage biopharmaceutical company specializing in next-generation, programmed T cell therapies. The company develops autologous CAR T cell th..
>Volltext.. |
| 388.67 Mio. EUR |
| 430.84 Mio. EUR |
| 64.46 Mio. EUR |
| -222.1 Mio. EUR |
| -245.53 Mio. EUR |
| -0.92 EUR |
| 300.27 Mio. EUR |
| 90.22 Mio. EUR |
| - |
| 4.12 |
| 645.87% |
| -30.44% |
| - |
| - |
| - |
| - |
| AUTOLUS |
| 14.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|